159 related articles for article (PubMed ID: 32145595)
1. Aplastic anemia in a patient with advanced lung adenocarcinoma during first line osimertinib: A case report and literature review.
Sala L; Mancin M; Pastore A; Seminati D; Cortinovis D; Bidoli P; Alberti A
Lung Cancer; 2020 Apr; 142():120-122. PubMed ID: 32145595
[TBL] [Abstract][Full Text] [Related]
2. Osimertinib alone as second-line treatment for brain metastases (BM) control may be more limited than for non-BM in advanced NSCLC patients with an acquired EGFR T790M mutation.
Li C; Nie W; Guo J; Xiong A; Zhong H; Chu T; Zhong R; Xu J; Lu J; Zheng X; Zhang B; Shen Y; Pan F; Han B; Zhang X
Respir Res; 2021 May; 22(1):145. PubMed ID: 33975616
[TBL] [Abstract][Full Text] [Related]
3. Osimertinib, a third-generation EGFR tyrosine kinase inhibitor: A retrospective multicenter study of its real-world efficacy and safety in advanced/recurrent non-small cell lung carcinoma.
Kishikawa T; Kasai T; Okada M; Nakachi I; Soda S; Arai R; Takigami A; Sata M
Thorac Cancer; 2020 Apr; 11(4):935-942. PubMed ID: 32129931
[TBL] [Abstract][Full Text] [Related]
4. Successful osimertinib retreatment after extremely early onset severe pneumonitis in first-line treatment of lung adenocarcinoma.
Ahn JH
Thorac Cancer; 2020 Sep; 11(9):2713-2716. PubMed ID: 32666714
[TBL] [Abstract][Full Text] [Related]
5. Dramatic Radiation Recall Pneumonitis Induced by Osimertinib after Palliative Thoracic Radiotherapy for Lung Cancer.
Sanchis-Borja M; Parrot A; Sroussi D; Rivin Del Campo E; Fallet V; Cadranel J
J Thorac Oncol; 2019 Oct; 14(10):e224-e226. PubMed ID: 31558233
[No Abstract] [Full Text] [Related]
6. Fingerprint loss during combination therapy using osimertinib and anlotinib: A case report.
Xie L; Feng Y; Sun J
J Clin Pharm Ther; 2022 Feb; 47(2):248-250. PubMed ID: 34240438
[TBL] [Abstract][Full Text] [Related]
7. Myositis in a Patient with Advanced Lung Cancer Treated with Osimertinib.
Fujioka S; Kitajima T; Itotani R
J Thorac Oncol; 2018 Aug; 13(8):e137-e139. PubMed ID: 30049374
[No Abstract] [Full Text] [Related]
8. Emergence of NOTCH2-NTRK1 After Osimertinib in a Patient With Lung Adenocarcinoma With Neuroendocrine Differentiation.
Lin G; Liu Y; Li H; Chen S; Guo Y
Clin Lung Cancer; 2021 Mar; 22(2):e157-e159. PubMed ID: 33158763
[No Abstract] [Full Text] [Related]
9. Osimertinib-Associated Toxic Epidermal Necrolysis in a Lung Cancer Patient Harboring an EGFR Mutation-A Case Report and a Review of the Literature.
Sato I; Mizuno H; Kataoka N; Kunimatsu Y; Tachibana Y; Sugimoto T; Tani N; Ogura Y; Hirose K; Takeda T
Medicina (Kaunas); 2020 Aug; 56(8):. PubMed ID: 32796633
[TBL] [Abstract][Full Text] [Related]
10. Clearing of circulating tumour DNA predicts clinical response to osimertinib in EGFR mutated lung cancer patients.
Boysen Fynboe Ebert E; McCulloch T; Holmskov Hansen K; Linnet H; Sorensen B; Meldgaard P
Lung Cancer; 2020 May; 143():67-72. PubMed ID: 32213382
[TBL] [Abstract][Full Text] [Related]
11. Overall Survival with Osimertinib in Untreated,
Ramalingam SS; Vansteenkiste J; Planchard D; Cho BC; Gray JE; Ohe Y; Zhou C; Reungwetwattana T; Cheng Y; Chewaskulyong B; Shah R; Cobo M; Lee KH; Cheema P; Tiseo M; John T; Lin MC; Imamura F; Kurata T; Todd A; Hodge R; Saggese M; Rukazenkov Y; Soria JC;
N Engl J Med; 2020 Jan; 382(1):41-50. PubMed ID: 31751012
[TBL] [Abstract][Full Text] [Related]
12. Negative impact of malignant effusion on osimertinib treatment for non-small cell lung cancer harboring EGFR mutation.
Kawamura T; Kenmotsu H; Kobayashi H; Omori S; Nakashima K; Wakuda K; Ono A; Naito T; Murakami H; Mori K; Endo M; Takahashi T
Invest New Drugs; 2020 Feb; 38(1):194-201. PubMed ID: 31183631
[TBL] [Abstract][Full Text] [Related]
13. Osimertinib in T790M-positive and -negative patients with EGFR-mutated advanced non-small cell lung cancer (the TREM-study).
Eide IJZ; Helland Å; Ekman S; Mellemgaard A; Hansen KH; Cicenas S; Koivunen J; Grønberg BH; Brustugun OT
Lung Cancer; 2020 May; 143():27-35. PubMed ID: 32200138
[TBL] [Abstract][Full Text] [Related]
14. Clinical Modality of Resistance and Subsequent Management of Patients with Advanced Non-small Cell Lung Cancer Failing Treatment with Osimertinib.
Mu Y; Hao X; Yang K; Ma D; Wang S; Xu Z; Li J; Xing P
Target Oncol; 2019 Jun; 14(3):335-342. PubMed ID: 31124059
[TBL] [Abstract][Full Text] [Related]
15. Cardiac Safety of Osimertinib: A Review of Data.
Ewer MS; Tekumalla SH; Walding A; Atuah KN
J Clin Oncol; 2021 Feb; 39(4):328-337. PubMed ID: 33356419
[TBL] [Abstract][Full Text] [Related]
16. A novel osimertinib-resistant human lung adenocarcinoma cell line harbouring mutant EGFR and activated IGF1R.
Makimoto G; Ninomiya K; Kubo T; Sunami R; Kato Y; Ichihara E; Ohashi K; Rai K; Hotta K; Tabata M; Maeda Y; Kiura K
Jpn J Clin Oncol; 2021 May; 51(6):956-965. PubMed ID: 33829270
[TBL] [Abstract][Full Text] [Related]
17. Osimertinib in Patients with T790M-Positive Advanced Non-small Cell Lung Cancer: Korean Subgroup Analysis from Phase II Studies.
Ahn MJ; Han JY; Kim DW; Cho BC; Kang JH; Kim SW; Yang JC; Mitsudomi T; Lee JS
Cancer Res Treat; 2020 Jan; 52(1):284-291. PubMed ID: 31345012
[TBL] [Abstract][Full Text] [Related]
18. Clinical characteristics of T790M-positive lung adenocarcinoma after resistance to epidermal growth factor receptor-tyrosine kinase inhibitors with an emphasis on brain metastasis and survival.
Joo JW; Hong MH; Shim HS
Lung Cancer; 2018 Jul; 121():12-17. PubMed ID: 29858020
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of osimertinib in treating EGFR-mutated advanced NSCLC: A meta-analysis.
Yi L; Fan J; Qian R; Luo P; Zhang J
Int J Cancer; 2019 Jul; 145(1):284-294. PubMed ID: 30613959
[TBL] [Abstract][Full Text] [Related]
20. Osimertinib for Japanese patients with T790M-positive advanced non-small-cell lung cancer: A pooled subgroup analysis.
Hirashima T; Satouchi M; Hida T; Nishio M; Kato T; Sakai H; Imamura F; Kiura K; Okamoto I; Kasahara K; Uchida H; Vowler SL; Mitsudomi T
Cancer Sci; 2019 Sep; 110(9):2884-2893. PubMed ID: 31265163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
